Gary Boone, MD
Adult Medicine · San Diego, CANPI 1073543781
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $132, 8.9 times the $15 reported in 2019.
Across 28 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$109
- Seqirus USA Inc$102
- Novartis$55
- Boston Scientific$52
- Lilly USA, LLC$52
- Biohaven Pharmaceuticals, Inc.$28
- plus $108 from 6 others
Across 662 payments — averaging $7392.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$4M
- Pfizer$665K
- AbbVie$265K
- Amgen$3K
- Eli Lilly$2K
- Sanofi Pasteur Inc.$1K
What the payments were for
- Food & beverage$505100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $109 |
| Seqirus USA Inc | 5 | $102 |
| Novartis | 3 | $55 |
| Boston Scientific | 3 | $52 |
| Lilly USA, LLC | 2 | $52 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| AstraZeneca | 1 | $24 |
| Lucid Diagnostics Inc. | 1 | $23 |
| Neuronetics, Inc. | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$505 in reported general payments places this provider in the 65th percentile of 221 adult medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $40,501 |
| FarxigaDapagliflozin Propanediol | 37 | $38,265 |
| OzempicSemaglutide | 20 | $17,641 |
| JardianceEmpagliflozin | 17 | $15,781 |
| Repatha SureclickEvolocumab | 12 | $7,685 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $6,128 |
| Celecoxib | 71 | $3,912 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $2,791 |
| Losartan Potassium | 158 | $1,940 |
| Rosuvastatin Calcium | 53 | $1,815 |
| Ezetimibe | 28 | $1,620 |
| Tamsulosin Hcl | 77 | $1,486 |
| Atorvastatin Calcium | 127 | $1,362 |
| Metoprolol Succinate | 59 | $1,283 |
| Oxycodone Hcl | 42 | $1,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $109 | $40,50140 claims |
| AstraZenecaFarxiga | $24 | $38,26537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 221 adult medicine providers in California.
Other adult medicine in San Diego
- Ildiko Gerbatsch BornemiszaSan Diego$2K
- Yasuko KidokoroSan Diego$1K
- Susan HutchinsonLaguna Hills$1M
- Natalia GuzmanLos Angeles$583K
- Richard FauselRancho Mirage$30K
- Benedicto EstoestaValley Springs$22K
- Antoine DipsiaW. Sacramento$21K
- Patrick WelchArroyo Grande$20K
- Craig BobsonManteca$19K
- Tin WongLos Angeles$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.